Intravitreal peptide hydrogel strategies for sustained antioxidant delivery are evaluated in a preclinical ocular hypertension model. Discover the experimental design and translational implications.
Key Takeaways
- RADA16-CA provided sustained carnosic acid release over 72 hours, peaking at six hours
- 1% (w/v) hydrogel showed the lowest stiffness and was suitable for intravitreal injection
- In a rat acute ocular hypertension model, treatment reduced ROS and pro‑inflammatory cytokines